Therapeutic Potential of Kaknaj (Physalis Alkekengi) in Unani Medicine: An Evidence-Based Review

Physalis alkekengi (Kaknaj/Habb-e-Kaknaj), belonging to the family Solanaceae, is an important medicinal plant extensivelydescribed in the Unani system of medicine. It has been traditionally employed for the management of renal and urinary tract disorders, particularly urolithiasis, dysuria, and inflammatory conditions. Classical Unani literature attributes multiple pharmacological properties to Kaknaj, including diuretic (mudirr-i-baul), lithotriptic (mufattit-i-hasat), antiinflammatory(muhallil-i-waram), and nephroprotective actions. Phytochemical studies have identified a wide range of bioactive constituents such as flavonoids, alkaloids, physalins, withanolides, polyphenols, and sterols. These compounds are responsible for its diverse pharmacological activities. Modern scientific investigations have provided supportive evidence for its traditional uses, demonstrating antioxidant, antimicrobial, antidiabetic, immunomodulatory, and anticancer effects. Notably, physalin A and related compounds have shown significant biological potential in experimental studies. This review critically integrates classical Unani descriptions with contemporary pharmacological findings to highlight the therapeutic relevance of Kaknaj. It further explores its potential mechanisms of action and emphasizes the need for well-designed clinical studies to validate its efficacy and safety. The study aims to bridge traditional knowledge with modern research, thereby facilitating its future application in evidence-based medicine and drug development.